NYSEHealth CareHealth Care EquipmentS&P SmallCap 600
$63.98
-2.55 (-3.83%)
Close of Nov 06, 2026 · end-of-day data
INSP 8-K filings in 2024
Every material Form 8-K Inspire Medical Systems filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Inspire Medical Systems reported third-quarter 2024 revenue of $203.2 million, up 33% from $153.3 million a year earlier, and diluted earnings per share of $0.60 compared with a loss of $0.29 per share in the prior-year quarter. The company raised its full-year 2024 revenue guidance to $793 million to $798 million from $788 million to $798 million, and raised its full-year diluted EPS guidance to $1.20 to $1.40 from $0.60 to $0.80.
Q3 2024 revenue $203.2 million, up 33% year over year; U.S. revenue $195.8 million
Q3 2024 net income $18.5 million; diluted EPS $0.60 versus a diluted net loss of $0.29 per share in Q3 2023
Full-year 2024 revenue guidance raised to $793 million to $798 million; EPS guidance raised to $1.20 to $1.40
Full-year 2024 gross margin guidance maintained at 83% to 85%
Inspire Medical Systems reported second-quarter 2024 revenue of $195.9 million, up 30% from a year earlier, and net income of $9.8 million, compared with a net loss of $12.0 million a year earlier. The company raised its full-year 2024 revenue and diluted EPS guidance and authorized its first share repurchase program, of up to $150.0 million.
Q2 2024 revenue $195.9 million, up 30% from $151.1 million; diluted EPS $0.32 vs. a $0.41 loss a year earlier
Full-year 2024 revenue guidance raised to $788 million-$798 million from $783 million-$793 million
Full-year 2024 diluted EPS guidance raised to $0.60-$0.80 from $0.10-$0.20, excluding any share repurchases
Board authorized repurchase of up to $150.0 million of common stock, the first in company history
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Inspire Medical Systems filing is on SEC EDGAR ↗. 8-K briefs of other companies →